http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
망막중심정맥폐쇄에 동반된 황반부종에서 라니비주맙 주입술의 단기 임상 효과
신혜영,지동현.Hye Young Shin. MD. Dong Hyun Jee. MD 대한안과학회 2011 대한안과학회지 Vol.52 No.9
Purpose: To evaluate the short-term efficacy of intravitreal ranibizumab injection in eyes with macular edema secondary to central retinal vein occlusion (CRVO). Methods: The records of 17 patients (17 eyes, 11 ischemic, six ischemic) who received an intravitreal ranibizumab injection for macular edema secondary to CRVO were retrospectively analyzed. The ophthalmic examination included best corrected visual acuity (BCVA) and central macular thickness (CMT) at baseline and follow-up visits. Results: After intravitreal ranibizumab injection, the mean BCVA improved from log MAR 1.25 ± 0.47 at baseline to log MAR 0.78 ± 0.49 at 4 weeks and to log MAR 0.81 ± 0.52 at 12 weeks (p < 0.05). Additionally, the mean CMT decreased from 679.4 ± 230.5 μm at baseline to 224.4 ± 129.9 μm at 4 weeks and to 271.6 ± 174.1 μm at 12 weeks (<em>p</em> < 0.001). In subgroup analysis, the decreases in CMT at 4 weeks and 12 weeks were similar in ischemic CRVO and non-ischemic CRVO, but no significant changes in visual acuity were found at 12 weeks in the ischemic CRVO group (<em>p</em> = 0.138). Ten eyes (58.8%) did not require re-injections for macular edema for up to 12 weeks. Conclusions: Intravitreal ranibizumab injection appeared to be an effective option for the treatment of macular edema secondary to central retinal vein occlusion. J Korean Ophthalmol Soc 2011;52(9):1048-1054